此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Transcranial Focused Ultrasound Neuromodulation for Post-Stroke Motor Dysfunction

2026年10月1日 更新者:Ming Chu、Jiangsu Taizhou People's Hospital

Transcranial Focused Ultrasound Neuromodulation in Post-Stroke Motor Dysfunction

This study aims to evaluate how transcranial focused ultrasound (tFUS) technology can promote neural network remodeling and functional recovery after stroke. By integrating signals from electroencephalography (EEG) and magnetic resonance imaging (MRI), the study will investigate how activating or inhibiting specific brain regions affects motor and cognitive recovery. The goal is to improve patients' motor and cognitive functions, reduce long-term disability, and enhance quality of life. The study also seeks to optimize stimulation parameters to maximize rehabilitation outcomes and explore the mechanisms underlying neuroprotection and functional reconstruction after stroke.

This is a case-control study involving a total of 60 participants. Participants will be ischemic stroke survivors aged 18-75 years, with first-ever stroke onset between 21 days and 6 months, stable vital signs, no consciousness disorders, and the ability to provide informed consent and cooperate with assessments. Eligible participants must have unilateral limb motor impairment, with an upper extremity modified Ashworth score ≤3, Brunnstrom stage II-V, and an upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60.

Participants will be assigned to either a neuromodulation group (receiving multi-modal neuromodulation targeting specific brain regions) or a control group (receiving sham stimulation or conventional treatment). Primary outcome measures include changes in FMA-UE scores, neuroimaging data (CT/MRI), EEG measurements (resting-state and task-state spectral power, functional connectivity), and laboratory markers (complete blood count, CRP, IL-6, S100β, BDNF). Secondary outcome measures include Brunnstrom stage, Ashworth grade, muscle strength, and patient comfort ratings. Safety will be monitored through blood routine tests, blood biochemistry, and coagulation function.

Statistical analysis will compare key indicator changes between the neuromodulation and control groups before and after intervention. Independent t-tests (for two groups) or ANOVA (for multiple groups) will be used to assess between-group differences, with non-parametric tests applied for data not following a normal distribution.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Jiangsu
      • Taizhou、Jiangsu、中国、225300
        • 招聘中
        • Taizhou People's Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • (1) Patients with a confirmed imaging diagnosis of first-ever ischemic stroke; (2) Unilateral limb motor involvement; (3) Modified Ashworth Scale (MAS) grade ≤3 for the upper extremity, Brunnstrom stage II-V, and upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60 (inclusive); (4) Age 18-75 years, onset within 21 days to 6 months, in the subacute or recovery phase; (5) Stable vital signs, no consciousness impairment, informed consent provided, ability to cooperate with clinical assessments, and approval obtained from the institutional ethics committee.

Exclusion Criteria:

  • (1) Contraindications to MRI; (2) Infarction involving the thalamus; (3) Risk of intracranial hemorrhage; (4) Presence of intracranial metallic foreign bodies, cardiac pacemakers, or cochlear implants; (5) Unstable medical condition, severe cognitive impairment or psychiatric disorders rendering the patient unable to comprehend the study or cooperate with assessments; (6) Conditions affecting limb motor function, including fractures, joint contractures, or severe limb spasticity; (7) Current use of medications that alter cortical excitability.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Neuromodulation Group

Multimodal neuromodulation targeting specific neural regions in addition to conventional therapy.

The transcranial focused ultrasound stimulation device employed in this study is the NeuroFUS DPX-500, equipped with a 4-element transducer array and the BrainSight neuronavigation system. Individualized modeling and target segmentation are performed using high-resolution structural MRI and CT images acquired at baseline. Target planning and neuronavigation are conducted based on intracranial acoustic field simulation. The total stimulation duration is 12 minutes, comprising 480 pulse trains with 0.5 seconds on and 1 second off, yielding a duty cycle of 20%.

假比较器:Control Group

Sham stimulation in addition to conventional therapy.

The control group receives sham stimulation during the neuromodulation phase. All procedural steps are identical to those of the experimental group, including neuronavigation positioning, application of coupling gel, and all other preparatory procedures; however, ultrasound stimulation is not activated. Participants in the control group wear bone-conduction headphones to simulate and counteract acoustic confounding. Group allocation information is blinded to participants.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Upper extremity Fugl-Meyer Assessment (UE-FMA) motor score
大体时间:Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)

Upper extremity motor function assessed by the Fugl-Meyer Assessment (motor subscale). Total score ranges from 0 to 66, with higher scores indicating better motor function.

Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)
Resting-state EEG spectral power
大体时间:Baseline (Day 1) and Day 7 (after the 5-day intervention)

Resting-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.

Baseline (Day 1) and Day 7 (after the 5-day intervention)
Task-state EEG spectral power
大体时间:Baseline (Day 1) and Day 7 (after the 5-day intervention)

Task-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.

Baseline (Day 1) and Day 7 (after the 5-day intervention)
Resting-state fMRI fractional ALFF (fALFF)
大体时间:Baseline (Day 1) and Day 7 (after the 5-day intervention)

fALFF derived from resting-state functional MRI, the ratio of low-frequency power to whole-frequency power.

Baseline (Day 1) and Day 7 (after the 5-day intervention)
Resting-state fMRI regional homogeneity (ReHo)
大体时间:Baseline (Day 1) and Day 7 (after the 5-day intervention)

ReHo (Kendall's coefficient of concordance) from resting-state functional MRI, reflecting local synchronization of neuronal activity.

Baseline (Day 1) and Day 7 (after the 5-day intervention)
Resting-state fMRI functional connectivity (FC)
大体时间:Baseline (Day 1) and Day 7 (after the 5-day intervention)

Functional connectivity between regions of interest derived from resting-state functional MRI (Fisher z-transformed correlation coefficients).

Baseline (Day 1) and Day 7 (after the 5-day intervention)

次要结果测量

结果测量
措施说明
大体时间
Brunnstrom recovery stage of the affected upper limb
大体时间:Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)

Motor recovery staged using the Brunnstrom approach, an ordinal scale from Stage 1 (flaccid, no movement) to Stage 6 (near-normal coordination), with higher stages indicating better motor recovery.

Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
Modified Ashworth Scale (MAS) grade of the affected upper limb
大体时间:Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)

Muscle spasticity graded with the Modified Ashworth Scale, an ordinal scale with 6 levels (0, 1, 1+, 2, 3, 4); higher grades indicate greater spasticity (a worse outcome).

Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
Fractional anisotropy (FA) on diffusion tensor imaging (DTI)
大体时间:Baseline (Day 1) and Day 7 (after the 5-day intervention)

White-matter fractional anisotropy measured by diffusion tensor imaging. Dimensionless (0-1), with higher values indicating greater directional coherence of water diffusion.

Baseline (Day 1) and Day 7 (after the 5-day intervention)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月9日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年3月31日

研究注册日期

首次提交

2026年5月18日

首先提交符合 QC 标准的

2026年6月5日

首次发布 (实际的)

2026年6月10日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared because the informed consent obtained from participants does not include provisions for sharing data outside the research team.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅